The country’s first scientifically-confirmed anti-diabetes Ayurvedic drug with DPP4 inhibitory activity, BGR-34 (Blood Glucose Regulator-34), was launched by Council for Scientific and Industrial Research (CSIR) recently at a press conference in Pune. BGR-34 has been designed for type-2 diabetes mellitus and scientifically validated for its efficacy and safety, said A K S Rawat, the principal senior scientist, CSIR-National Botanical Research Institute (NBRI).
Sanjeev Kumar Ojha, senior scientist, CSIR- NBRI, Lucknow, Dayanandan Mani, senior scientist, CSIR-Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, Medha Kulkarni, vice principal, D Y Patil Ayurvedic College and Research Centre, Pune, and S P Srivastav, director, AIMIL Pharmaceuticals (India) Ltd, were also present on the occasion.
- Lung capacity of Indians 30% lower than North Americans: Scientist
- CSIR-NCL senior scientist becomes NASI fellow
- PM Modi to inaugurate first ever All India Institute of Ayurveda
- Last decade, over half of Shanti Swarup winners from three institutions, just seven women amongst awardees
- Government announces recipients of Shanti Swarup Bhatnagar award
- CIMAP,IPCA join hands to grow herbs for anti-malaria drugs in UP
Developed jointly by NBRI and CIMAP, the research units of CSIR situated at Lucknow, BGR-34 has been economically priced at Rs 5 per tablet as compared to the latest DPP4 inhibitors, globally.
A K S Rawat said, “The 6-crore adult Indian population has been found to be diabetic and there is no effective solution for diabetes as yet. We are sure that eminent medical professionals will recommend BGR-34 to their patients suffering from type 2 Diabetes mellitus for quicker and consistent response. CSIR’s premier research institutions have developed and established the efficacy of BGR-34.”